Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible

Clinical Breast Cancer

Volumn 8, Issue 5, 2008, Pages 418-424

  Dang, Chau ^a   D'Andrea, Gabriella ^a   Lake, Diana ^a   Sugarman, Steve ^a   Fornier, Monica ^a   Moynahan, Mary Ellen ^a   Gilewski, Theresa ^a   Hurria, Arti ^a   Mills, Nancy ^a   Troso Sandoval, Tiffany ^a   George, Roshini ^a   Robson, Mark ^a   Dickler, Maura ^a   Smith, Karen ^a   Panageas, Katherine ^a   Norton, Larry ^a   Hudis, Clifford ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adjuvant chemotherapy; Pegfilgrastim

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; ENALAPRIL; EPIRUBICIN; FLUOROURACIL; GRANISETRON; HISTAMINE H2 RECEPTOR ANTAGONIST; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; BLOOD TRANSFUSION; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONSTIPATION; COUGHING; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; LEUKOPENIA; LYMPH NODE; MASTECTOMY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PILOT STUDY; PLEURA EFFUSION; PNEUMONIA; PREOPERATIVE EVALUATION; SENSORY NEUROPATHY; SIDE EFFECT; SURGICAL TECHNIQUE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME; BREAST TUMOR; CLINICAL TRIAL; MIDDLE AGED;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL; PILOT PROJECTS;

EID: 58149242954     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2008.n.050     Document Type: Article

References (44)

1. Sparano JA, Wang M, Martino S, et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. Breast Cancer Res Treat 2005; 94 (suppl 1):S20 (Abstract 48).
2. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352:2302-13.
3. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006; 24:5381-7.
4. The French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-Year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001; 19:602-11
5. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354:809-20.
6. Miller K, Wang M, Gralaw J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-76.
7. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 2005; 365:1687-717.
8. Fisher B, Bauer M, Wickerman DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 1983; 52:1551-7.
9. Saez RA, McGuire WL, Clark G.M. Prognostic factors in breast cancer. Sem Surg Oncol 1989; 5:102-10.
10. Dang CT, Gilewski TA, Surbone A, et al. Cytokinetics. In: Holland JF, Frei E, III, Bast RC, Jr, et al, eds. Cancer Medicine. 6th Edition. Baltimore: Williams and Wilkins; 2003: 645-68.
11. Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first line therapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003; 21:968-75.
12. Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001; 19:1707-15.
13. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21:976-83.
14. Mamounas EP, Bryant J, Lembersky BC, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP-B 28. J Clin Oncol 2005; 23:3686-96.
15. Levine MN, Pritchard KI, Bramwell VH, et al. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group MA.5. J Clin Oncol 2005; 23:5166-70.
16. Roche H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicinbased and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 2006; 24:5664-71.
17. Martin M, Rodriguez-Lescure A, Ruiz A, et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 2008; 100:805-14.
18. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986; 4:1162-70.
19. Von Hoff DD, Clark GM, Weiss GR, et al. Use of in vitro dose-response effect to select antineoplastics for high-dose or regional administration regimens. J Clin Oncol 1986; 4:1827-34.
20. Fisher B, Anderson S, Wickerham DL, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997; 15:1858-69.
21. Fisher B, Anderson S, DeCillis A, et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 1999; 17:3374-88.
22. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986; 70:163-9.
23. Bonadonna G, Zambette M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 1995; 273:542-7.
24. Hudis C, Seidman A, Baselga J, et al. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for respectable high-risk breast cancer: feasibility and efficacy. J Clin Oncol 1999; 17:93-100.
25. Hudis C, Fornier M, Riccio L, et al. 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: a phase II study. J Clin Oncol 1999; 17:1118.
26. Fornier MN, Seidman AD, Theodoulou M, et al. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. Clin Cancer Res 2001; 7:3934-41.
27. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21:1431-9.
28. Hudis C, Citron M, Berry D, et al. Five year follow-up of INT C9741: dose-dense chemotherapy is safe and effective. Breast Cancer Res Treat 2005; 94(suppl 1):S20 (Abstract 49).
29. Dang CT, D'Andrea G, Moynahan M, et al. Phase II study of dose-dense 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) followed by alternating weekly paclitaxel and docetaxel in high-risk, 4 or more node-positive breast cancer: feasibility. Clin Cancer Res 2004; 10:5754-61.
30. Therasse P, Mauriac L, Welnicka-Jadkiewicz M, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin ad cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003; 21:843-50.
31. Untch M, Thomssen C, Steffen K, et al. Five year results of a randomized multicenter dose intense (DI-EC) study with epirubicin (E) and cyclophosphamide (C) in high risk breast cancer patients-a treatment of short duration with comparable efficacy to conventional chemotherapy. Breast Cancer Res Treat 2002; 70:641a.
32. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer. N Engl J Med 2005; 353:1673-84.
33. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2 positive breast cancer. N Engl J Med 2005; 353:1659-72.
34. Crown J, Francis P, Di Leo A, et al. Docetaxel given concurrently or sequentially to anthracycline-based adjuvant therapy for patients with node-positive breast cancer. A comparison with non-taxane combination chemotherapy. First results of the BIG 2-98 trial at 5 years median follow-up. J Clin Oncol 2006; 24(18 suppl):7s (Abstract LBA519).
35. Bianco AR, De Matteis A, Manzione L, et al. Sequential epirubicin-docetaxel-CMF as adjuvant therapy of early breast cancer: results of the Taxit 216 multicenter phase III trial. J Clin Oncol 2006; 24(18 suppl):8s (Abstract LBA520).
36. De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008; 26:44-53.
37. Jones S, Holmes F, O'Shaughnessy J, et al. Extended follow-up and analysis by age of the US Oncology trial 9735: docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/ cyclophosphamide and is well tolerated in women 65 or older. Presented at: The 2007 Annual San Antonio Breast Cancer Symposium; San Antonio, TX; December 13-16, 2007. Abstract 12.
38. Fornier MN, Seidman AD, Lake D, et al. Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10-11-day intervals with filgrastim support in women with breast cancer. Clin Cancer Res 2007; 13:223-7.
39. National Comprehensive Cancer Network. Cancer-and Treatment-Related Anemia. Available at: http://www.nccn.org/ professionals/physician-gls/PDF/anemia. pdf
40. Sheperd LE, Parulekar W, Pritchard KI, et al. Left ventricular function following adjuvant chemotherapy for breast cancer: The NCIC CTG MA.5 experience. J Clin Oncol 2006; 24(18 suppl):8s (Abstract 522).
41. Gennari A, Sormani MP, Pronzato P, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008; 100:14-20.
42. Knoop AS, Knudsen H, Balslev E, et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil. J Clin Oncol 2005; 23:7483-90.
43. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer: a randomized controlled trial. Lancet 2007; 369:29-36.
44. Slamon DJ, Eiermann W, Robert NJ, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res 2005; 94(suppl 1):S5.